STOCK TITAN

Abbott Laboratories - ABT STOCK NEWS

Welcome to our dedicated news page for Abbott Laboratories (Ticker: ABT), a resource for investors and traders seeking the latest updates and insights on Abbott Laboratories.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Abbott Laboratories's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Abbott Laboratories's position in the market.

News
Rhea-AI Summary
Abbott joins Billion Dollar Roundtable, spending $1.7 billion with diverse suppliers in 2022, an increase of 63% from prior year. Supplier diversity efforts support over 7,500 jobs and generate over $4.5 billion in economic impact in the U.S.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.88%
Tags
none
-
Rhea-AI Summary
Abbott announces acquisition of Bigfoot Biomedical, a leader in smart insulin management systems for people with diabetes. The transaction is expected to close in Q3 2023. Financial terms were not disclosed.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.67%
Tags
-
Rhea-AI Summary
Abbott reports second-quarter financial results with sales of $10.0 billion and strong growth in underlying base business. Adjusted diluted EPS of $1.08. Full-year 2023 outlook remains unchanged.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.24%
Tags
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.45%
Tags
none
-
Rhea-AI Summary
Abbott receives FDA approval for the world's first dual chamber leadless pacemaker system, expanding access to leadless pacing for millions of people. The system utilizes Abbott's proprietary i2i communication technology to provide synchronized cardiac pacing between two leadless pacemakers.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.14%
Tags
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.05%
Tags
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.17%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.88%
Tags
none
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.9%
Tags
dividends
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.1%
Tags
none
Abbott Laboratories

NYSE:ABT

ABT Rankings

ABT Stock Data

189.50B
1.72B
0.54%
77.02%
0.83%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States
North Chicago

About ABT

Abbott Laboratories is an American multinational medical devices and health care company with headquarters in Abbott Park, Illinois, United States.